A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
This study is testing a new experimental medication called D3S-002, either alone or with another drug called D3S-001, in adults with advanced solid tumors. Researchers want to find the safest and most effective dose of this medication for people whose cancers have specific genetic changes in the MAPK cell signaling pathway.
You may be able to join if you are an adult with advanced cancer or non-small cell lung cancer that has grown or worsened, and tests show you have a specific MAPK pathway genetic mutation. You must also meet certain health guidelines and not have untreated brain metastases or other serious medical conditions.
Participants will take the experimental study medication by mouth every day in repeating 21-day cycles. Doctors will closely monitor your health, safety, and how your body processes the medicine throughout the study.
This study is currently recruiting participants at locations in Detroit, Michigan; New York, New York; and Nashville, Tennessee. It is a first-in-human trial looking at safety and finding the right dose for future studies.
- 1Tests a new medication, D3S-002, for advanced solid tumors and lung cancer.
- 2Requires participants to have a specific genetic mutation known as a MAPK pathway mutation.
- 3Currently recruiting patients in select cities across the United States.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.